medigraphic.com
ISSN 2221-2434 (Electronic)

2016, Number 4

<< Back Next >>

Finlay 2016; 6 (4)

Genetic factors for breast carcinogenesis

Miguel-Soca PE, Argüelles GI, Peña GM

Language: Spanish
References: 62
Page: 299-316
PDF size: 969.15 Kb.


ABSTRACT

Breast cancer is a multifactorial genenetic disease in which oncogenes derived from normal cellular genes intervene, which constitute positive signals of cellular proliferation and tumour suppressor genes and represent negative signals of cells multiplication and differentiation. Although these alterations which affect germinal cells produce inherited cancers, in most of the cases somatic cell genes are affected. To the susceptibility of cancer due to genes as BRCA1 and BCRA2, the effect of factors associated to environment, life style and toxic habits are added, these determine a complex interrelation genes-environment which imply an activation of oncogenes and inactivation of tumour suppressors. The objective of this review in to offer an updated view about the main genes implied in breast carcinogenesis. The topic is controversial y currently deeply investigated.


REFERENCES

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin [revista en Internet]. 2015 [citado 22 Sep 2016];65(2):[aprox. 20p]. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/caac.2 1262/full

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin [revista en Internet]. 2015 [citado 25 Sep 2016];65(1):[aprox. 15p]. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/caac.2 1254/full

  3. Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YCT, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA [revista en Internet]. 2015 [citado 4 Sep 2016];314(15):[aprox. 15p]. Disponible en: http://jama.jamanetwork.com/article.aspx?articlei d=2463262#tab6

  4. Coronado GD, Beasley J, Livaudais J. Alcohol consumption and the risk of breast cancer. Salud Pública Méx [revista en Internet]. 2011 [citado 15 Sep 2016];53(5):[aprox. 8p]. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_ar ttext&pid=S0036-36342011000500012&lng=es

  5. Cuenca C, Despaigne AE, Beltrán Y. Factores de riesgo de cáncer de mama en mujeres pertenecientes a un consultorio médico del Centro Urbano ¨José Martí¨. MEDISAN [revista en Internet]. 2013 [citado 5 Ene 2016];17(9):[aprox. 6p]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_a rttext&pid=S1029-30192013000900005&lng=es

  6. Núñez AC, Frómeta CI, Rubio T. Factores ambientales y genéticos asociados al cáncer de mama en féminas del área de salud ¨28 de Septiembre¨. MEDISAN [revista en Internet]. 2011 [citado 30 Sep 2016];15(2):[aprox. 8p]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_a rttext&pid=S1029-30192011000200003&lng=es

  7. Aguilar MJ, Neri M, Padilla CA, Pimentel ML, García A, Sánchez AM. Factores de riesgo como pronóstico de padecer cáncer de mama en un estado de México. Nutr Hosp [revista en Internet]. 2012 [citado 22 Sep 2016];27(5):[aprox. 6p]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext &pid=S0212-16112012000500038&lng=es

  8. Chlebowski RT, Anderson GL. Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf [revista en Internet]. 2015 [citado 2 Sep 2016];6(2):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC44 06918

  9. Antoine C, Ameye L, Paesmans M, Rozenberg S.. Systematic review about breast cancer incidence in relation to hormone replacement therapy use. Climacteric [revista en Internet]. 2014 [citado 12 Sep 2016];17(2):[aprox. 20p]. Disponible en: http://www.tandfonline.com/doi/full/10.3109/136 97137.2013.829812

  10. Salagame U, Banks E, Sitas F, Canfell K. Menopausal hormone therapy use and breast cancer risk in Australia: findings from the New South Wales Cancer Lifestyle and EvAluation of Risk (CLEAR) study. Int J Cancer [revista en Internet]. 2016 [citado 2 Nov 2016];138(8):[aprox. 15p]. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/ijc.299 42/epdf

  11. Rose DP, Gracheck PJ, Vona-Davis L. The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer. Cancers (Basel) [revista en Internet]. 2015 [citado 2 Sep 2016];7(4):[aprox. 20p]. Disponible en: http://www.mdpi.com/2072-6694/7/4/0883/htm

  12. Boonyaratanakornkit V, Pateetin P. The role of ovarian sex steroids in metabolic homeostasis, obesity, and postmenopausal breast cancer: molecular mechanisms and therapeutic implications. Biomed Res Int [revista en Internet]. 2015 [citado 2 Sep 2016]; :[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 83469

  13. Harvie M, Howell A, Evans DG. Can diet and lifestyle prevent breast cancer: what is the evidence?. Am Soc Clin Oncol Educ Book [revista en Internet]. 2015 [citado 2 Sep 2016];35(1):[aprox. 8p]. Disponible en: http://meetinglibrary.asco.org/content/11500066- 156

  14. Torres L. Superación profesional: una alternativa para el diagnóstico precoz del cáncer de mama. Medisur [revista en Internet]. 2012 [citado 12 Dic 2015];10(2):[aprox. 10p]. Disponible en: http://medisur.sld.cu/index.php/medisur/article/vi ew/1980/920

  15. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist [revista en Internet]. 2004 [citado 2 Nov 2015];9(4):[aprox. 15p]. Disponible en: http://theoncologist.alphamedpress.org/content/9 /4/361.long

  16. Padrón J, Padrón L, Padrón L, Morejón AF, Benet M. Comportamiento del diagnóstico precoz del cáncer de mama y cérvicouterino en el municipio Cienfuegos. Finlay [revista en Internet]. 2013 [citado 14 Mar 2016];3(2):[aprox. 7p]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/vie w/187

  17. Torres L, Iglesias M, Zerquera C. Repercusión de la implementación del Diplomado de Mastología en la provincia de Cienfuegos. Medisur [revista en Internet]. 2011 [citado 14 Mar 2016];9(5):[aprox. 5p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext& pid=S1727-897X2011000500005&lng=es

  18. Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med [revista en Internet]. 2015 [citado 2 Sep 2016];13(1):[aprox. 13p]. Disponible en: http://www.biomedcentral.com/1741-7015/13/46

  19. Latasa P, Gandarillas AM, Ordobas M. Tendencias y desigualdades sociales en el cribado de cáncer de cérvix y cáncer de mama en la Comunidad de Madrid durante el periodo 1995-2010 a partir del Sistema de Vigilancia de Factores de Riesgo de enfermedades no transmisibles (SIVFRENT-A). Anales Sis San Navarra [revista en Internet]. 2015 [citado 9 Sep 2016];38(1):[aprox. 10p]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext &pid=S1137-66272015000100003&lng=es

  20. Vich P, Brusint B, Álvarez C, Cuadrado C, Díaz N, Redondo E. Actualización del cáncer de mama en Atención Primaria (I/V). Semergen [revista en Internet]. 2014 [citado 2 Nov 2015];40(6):[aprox. 5p]. Disponible en: http://dx.doi.org/10.1016/j.semerg.2014.02.012

  21. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Prz Menopauzalny [revista en Internet]. 2015 [citado 2 Sep 2016];14(3):[aprox. 7p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC46 12558

  22. Dieterich M, Stubert J, Reimer T, Erickson N, Berling A. Influence of lifestyle factors on breast cancer risk. Breast Care (Basel) [revista en Internet]. 2014 [citado 2 Nov 2015];9(6):[aprox. 7p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 17679

  23. Murria R, Palanca S, de Juan I, Egoavil C, Alenda C, García Z, et al. Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer. Am J Cancer Res [revista en Internet]. 2014 [citado 2 Sep 2016];5(1):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 00703

  24. Miguel PE, Almaguer A, Ponce de León D, Sales H, Pérez H. El cáncer una enfermedad genética. CCM [revista en Internet]. 2007 [citado 2 Nov 2015];11(3):[aprox. 8p]. Disponible en: http://www.cocmed.sld.cu/no113/n113rev1.htm

  25. Weitzel JN. The Genetics of Breast Cancer. What the Surgical Oncologist Needs to Know. Surg Oncol Clin N Am [revista en Internet]. 2015 [citado 2 Sep 2016];24(4):[aprox. 20p]. Disponible en: http://dx.doi.org/10.1016/j.soc.2015.06.011

  26. Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev [revista en Internet]. 2015 [citado 2 Nov 2016];41(1):[aprox. 7p]. Disponible en: http://dx.doi.org/10.1016/j.ctrv.2014.10.008

  27. Maxwell KN, Nathanson KL. Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res [revista en Internet]. 2013 [citado 2 Nov 2015];15(6):[aprox. 3p]. Disponible en: http://breast-cancer-research.com/content/15/6/2 12

  28. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget [revista en Internet]. 2014 [citado 2 Nov 2015];5(13):[aprox. 20p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC41 48087

  29. Vogt PK. Retroviral Oncogenes: A Historical Primer. Nat Rev Cancer [revista en Internet]. 2012 [citado 2 Nov 2015];12(9):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC34 28493

  30. Shortt J, Johnstone RW. Oncogenes in Cell Survival and Cell Death. Cold Spring Harb Perspect Biol [revista en Internet]. 2012 [citado 2 Nov 2015];4(12):[aprox. 8p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC35 04432

  31. Bagci O, Kurtgöz S. Amplification of Cellular Oncogenes in Solid Tumors. N Am J Med Sci [revista en Internet]. 2015 [citado 2 Sep 2016];7(8):[aprox. 7p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45 61439

  32. Omenn GS, Guan Y, Menon R. A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines. J Proteomics [revista en Internet]. 2014 [citado 2 Sep 2016];107(1):[aprox. 9p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC41 23867

  33. Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, et al. Triple positive breast cancer: a distinct subtype?. Cancer Treat Rev [revista en Internet]. 2015 [citado 2 Sep 2016];41(2):[aprox. 7p]. Disponible en: http://dx.doi.org/10.1016/j.ctrv.2014.12.005

  34. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med [revista en Internet]. 2014 [citado 2 Nov 2015];7(1):[aprox. 12p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC41 57397

  35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature [revista en Internet]. 2012 [citado 2 Nov 2015];490(7418):[aprox. 9p]. Disponible en: http://www.nature.com/nature/journal/v490/n741 8/full/nature11412.html

  36. He X, Xiang H, Zong X, Yan X, Yu Y, Liu G, et al. CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro. Cancer Cell Int [revista en Internet]. 2014 [citado 2 Nov 2015];14(1):[aprox. 5p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC42 79590

  37. Ullah A, Mahjabeen I, Kayani MA. Genetic polymorphisms in cell cycle regulatory genes CCND1 and CDK4 are associated with susceptibility to breast cancer. J BUON [revista en Internet]. 2015 [citado 2 Sep 2016];20(4):[aprox. 8p]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26416047

  38. Chen BJ, Wu YL, Tanaka Y, Zhang W. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci [revista en Internet]. 2014 [citado 2 Nov 2015];10(10):[aprox. 12p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC42 02025

  39. Dey N, Leyland B, De P. MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res [revista en Internet]. 2014 [citado 2 Nov 2015];5(1):[aprox. 19p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 00701

  40. Minuti G, Landi L. MET deregulation in breast cancer. Ann Transl Med [revista en Internet]. 2015 [citado 2 Sep 2016];3(13):[aprox. 3p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45 43340

  41. Graveel CR, Tolbert D, Woude GV. MET: A Critical Player in Tumorigenesis and Therapeutic Target. Cold Spring Harb Perspect Biol [revista en Internet]. 2013 [citado 2 Nov 2015];5(7):[aprox. 9p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC36 85898

  42. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA [revista en Internet]. 2009 [citado 2 Nov 2015];106(31):[aprox. 5p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27 22304

  43. Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res [revista en Internet]. 2015 [citado 2 Sep 2016];17(1):[aprox. 2p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 89345

  44. Yang ZY, Di MY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, et al. The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Sci Rep [revista en Internet]. 2015 [citado 2 Sep 2016];5(1):[aprox. 6p]. Disponible en: http://www.nature.com/articles/srep07758

  45. Faes S, Dormond O. PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci [revista en Internet]. 2015 [citado 2 Sep 2016];16(9):[aprox. 15p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC46 13246

  46. Scalia J, Colins BL, Penson RT, Dizon DS. Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. Semin Radiat Oncol [revista en Internet]. 2016 [citado 2 Nov 2016];26(1):[aprox. 5p]. Disponible en: http://www.semradonc.com/article/S1053-4296(1 5)00095-8/pdf

  47. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido I, et al. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med [revista en Internet]. 2014 [citado 2 Nov 2015];18(101):[aprox. 8p]. Disponible en: http://www.discoverymedicine.com/Rishi-Agarwal /2014/12/targeted-therapy-of-hereditary-cancer-s yndromes-hereditary-breast-and-ovarian-cancer-syndrome-lynch-syndrome-familial-adenomatouspolyposis-and-li-fraumeni-syndrome

  48. Ortigoza RI, Miguel PE, Machín D. Variantes genéticas en el cáncer de mama. CCM [revista en Internet]. 2012 [citado 2 Nov 2015];16(4):[aprox. 6p]. Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article /view/737/230

  49. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis [revista en Internet]. 2012 [citado 2 Nov 2015];33(11):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC34 83014

  50. Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, et al. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. Br J Cancer [revista en Internet]. 2015 [citado 2 Sep 2016];112(6):[aprox. 7p]. Disponible en: http://www.nature.com/bjc/journal/v112/n6/full/bj c201560a.html

  51. Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, et al. Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis [revista en Internet]. 2015 [citado 2 Sep 2016];4(1):[aprox. 9p]. Disponible en: http://www.nature.com/oncsis/journal/v4/n10/full/ oncsis201527a.html

  52. Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res [revista en Internet]. 2014 [citado 2 Nov 2015];16(3):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40 76637

  53. Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast Cancer Res [revista en Internet]. 2012 [citado 2 Nov 2015];14(1):[aprox. 2p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC34 96113

  54. Asiaf A, Ahmad ST, Aziz SA, Malik AA, Rasool Z, Masood A, Zargar MA. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir. Asian Pac J Cancer Prev [revista en Internet]. 2014 [citado 2 Nov 2015];15(15):[aprox. 6p]. Disponible en: http://www.apocpcontrol.org/paper_file/issue_abs /Volume15_No15/6397-6403 6.4 Asia Asiaf.pdf

  55. Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int [revista en Internet]. 2014 [citado 2 Nov 2015];2014(1):[aprox. 10p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC41 82303

  56. MacNeil AJ, Jiao SC, McEachern LA, Yang YJ, Dennis A, Yu H, et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Res [revista en Internet]. 2014 [citado 2 Feb 2016];74(1):[aprox. 10p]. Disponible en: http://cancerres.aacrjournals.org/content/74/1/16 2.long

  57. García C, Cortijo S, Cañamares I, Goyache MP, Ferrari JM. Lapatinib en combinación con trastuzumab en el tratamiento del cáncer de mama metastásico HER-2 positivo: experiencia de uso. Farm Hosp [revista en Internet]. 2014 [citado 14 Dic 2015];38(2):[aprox. 5p]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext &pid=S1130-63432014000200009&lng=es

  58. Germain D. Estrogen Carcinogenesis in Breast Cancer. Endocrinol Metab Clin North Am [revista en Internet]. 2011 [citado 12 Nov 2015];40(3):[aprox. 11p]. Disponible en: https://www.clinicalkey.es/ui/service/content/url? eid=1-s2.0-S0889852911000582

  59. Stuckey AR, Onstad MA. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015. Am J Obstet Gynecol [revista en Internet]. 2015 [citado 2 Sep 2016];213(2):[aprox. 6p]. Disponible en: http://dx.doi.org/10.1016/j.ajog.2015.03.003

  60. Tavtigian SV, Chenevix G. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med [revista en Internet]. 2014 [citado 2 Nov 2015];8(4):[aprox. 15p]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43 36165

  61. Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene [revista en Internet]. 2015 [citado 2 Sep 2016];34(1):[aprox. 13p]. Disponible en: http://www.nature.com/onc/journal/v34/n1/full/on c2013570a.html

  62. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet [revista en Internet]. 2007 [citado 23 Mar 2016];8(10):[aprox. 13p]. Disponible en: http://www.nature.com/nrg/journal/v8/n10/full/nr g2159.html




2020     |     www.medigraphic.com